In early 2020, South Korea experienced a large coronavirus disease 2019 (COVID-19) outbreak. However, despite its proximity to China, where the virus had emerged, and the high population density of the Seoul metropolitan area, a major international hub, South Korea effectively contained the spread of COVID-19 using non-pharmaceutical interventions until vaccine distribution in 2021. Here, we built a metapopulation model with a susceptible-exposed- infectious-quarantined-recovered (SEIQR) structure and combined it with the ensemble adjustment Kalman filter to infer the transmission dynamics of COVID-19 in South Korea from February 2020 until vaccine deployment. Over the study period, the fraction of documented infections (ascertainment rate) was found to increase from 0.50 (95% credible interval (CI): 0.26—0.77) to 0.62 (95% CI: 0.39—0.86). The cumulative number of total infections, including both documented cases and undocumented infections, was less than 1% of the South Korean population at the end of the simulation period, indicating that the majority of people had yet to be infected when vaccine administration began. These findings enhance understanding of the COVID-19 outbreak in South Korea and highlight the importance of preparedness and response in managing global pandemics.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes